KB-1505

Blinatumomab

45816

Background of Blinatumomab

Blinatumomab is a monoclonal antibody of the BiTE (bispecific T-cell engager) class, engineered through the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV via a short peptide linker. CD3 is an antigen present on T-cell surfaces, while CD19 is predominantly found on malignant B-cells. By binding to both antigens, blinatumomab effectively redirects T-cells towards tumor cells expressing CD19, thereby facilitating tumor cell lysis and apoptosis. Blinatumomab has been particularly noted for its efficacy in treating relapsed or refractory acute lymphoblastic leukemia (ALL), demonstrating significant response rates in clinical trials. Its unique design not only enhances specificity but also minimizes off-target effects, making it a promising candidate in targeted cancer therapies.

Specifications

Catalog Number	KB-1505
Antibody Name	Blinatumomab
Isotype	ScFv
Target	CD19&CD3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS\|T cell activation\|Cell killing
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Zugmaier G, Klinger M, Schmidt M, Subklewe M: Clinical overview of anti-CD19 BiTE((R)) and ex vivo data from anti-CD33 BiTE((R)) as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015 Oct;67(2 Pt A):58-66.